Title A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan
Authors Bennett, Heather
Waser, Nathalie
Johnston, Karissa
Kao, Jia-Horng
Lim, Young-Suk
Duan, Zhong-Ping
Lee, Youn-Jae
Wei, Lai
Chen, Chien-Jen
Sievert, William
Yuan, Yong
Li, Hong
Affiliation ICON Plc, ICON Epidemiol, Toronto, ON, Canada.
ICON Plc, ICON Epidemiol, Vancouver, BC, Canada.
Natl Taiwan Univ, Coll Med, Dept Internal Med, Natl Taiwan Univ Hosp, Taipei, Taiwan.
Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan.
Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea.
Beijing Capital Med Univ, Yon An Hosp, Beijing, Peoples R China.
Inje Univ, Coll Med, Busan Paik Hosp, Dept Internal Med, Busan, South Korea.
Peking Univ, Peoples Hosp, Inst Hepatol, Beijing 100871, Peoples R China.
Natl Taiwan Univ, Acad Siica, Taipei 10764, Taiwan.
Monash Univ, Monash Hlth, Melbourne, Vic 3004, Australia.
Bristol Myers Squibb Co, Princeton, NJ USA.
Keywords Hepatitis C virus
Epidemiology
Prevalence
Incidence
Genotype
Complications of HCV infection
METHADONE-MAINTENANCE TREATMENT
VIRAL-HEPATITIS
PREVALENCE
EPIDEMIOLOGY
AREA
HIV
COINFECTIONS
POPULATION
SHANGHAI
PROVINCE
Issue Date 2015
Publisher HEPATOLOGY INTERNATIONAL
Citation HEPATOLOGY INTERNATIONAL.2015,9,(3),378-390.
Abstract Hepatitis C virus (HCV) infection is associated with substantial clinical and economic burden and is an important public health issue in Asia. The objective of this review was to characterize HCV epidemiology and related complications in China, Japan, South Korea and Taiwan. A search of electronic databases and conference abstracts identified 71 potentially relevant articles. Of those, 55 were included in the epidemiology review and 9 in the review of HCV-related complications. HCV prevalence in the general population was 1.6 % in China, 0.6-0.9 % in Japan, 0.6-1.1 % in South Korea and 1.8-5.5 % in Taiwan. Prevalence was higher for injecting drug users (48-90 %) and those with human immunodeficiency virus coinfection (32-85 %) and was lower for blood donors (< 1 %). Annual incidence of HCV in China was 6.01 per 100,000. HCV genotype 1b was associated with the highest incidence of hepatocellular carcinoma (HCC). Five-year survival for patients with liver cirrhosis was 73.8 %, decreasing to 39.2 % following liver transplantation; the majority of deaths were attributable to HCC. Limitations were that the majority of studies included in the epidemiology review were small, regional studies conducted in specific populations, and there was an absence of large population-based studies. Thus, estimates may not be representative of the epidemiology of HCV for each country. The prevalence HCV in China and HCV incidence in the Asian region remain largely unknown, and they are likely underestimated. Further epidemiologic and clinical data are needed to provide more precise estimates for use by public health agencies.
URI http://hdl.handle.net/20.500.11897/418929
ISSN 1936-0533
DOI 10.1007/s12072-015-9629-x
Indexed SCI(E)
Appears in Collections: 人民医院

Files in This Work
There are no files associated with this item.

Web of Science®


0

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.